NASDAQ: MDBHMdb Capital Holdings LLC Stock
$3.66+0.21 (+6.09%)
Updated Apr 10, 2026
MDBH Price
$3.66
Fair Value Price
$2.63
Market Cap
$37.69M
52 Week Low
$2.75
52 Week High
$5.50
P/E
-1.74x
P/B
0.62x
P/S
3.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.91M
Earnings
-$21.25M
Gross Margin
100%
Operating Margin
-432.38%
Profit Margin
-432.6%
Debt to Equity
0.05
Operating Cash Flow
-$6M
Beta
0.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDBH Overview
MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDBH's potential to beat the market
- MDBH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Capital Market
Industry Rating
F
MDBH
RankedUnranked of 62
RankedUnranked of 62
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $105.11 | A | |
| $48.62 | A | |
| $10.92 | A |
Be the first to know about important MDBH news, forecast changes, insider trades & much more!
MDBH News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDBH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDBH ($3.66) is overvalued by 39.05% relative to our estimate of its Fair Value price of $2.63 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MDBH ($3.66) is not significantly undervalued (39.05%) relative to our estimate of its Fair Value price of $2.63 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MDBH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MDBH due diligence checks available for Premium users.
Valuation
MDBH fair value
Fair Value of MDBH stock based on Discounted Cash Flow (DCF)
Price
$3.66
Fair Value
$2.63
Overvalued by
39.09%
MDBH ($3.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDBH ($3.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDBH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDBH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.74x
Industry
13.55x
Market
29.91x
MDBH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.62x
Industry
2.72x
MDBH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDBH's financial health
Profit margin
Revenue
$4.7M
Net Income
-$1.8M
Profit Margin
-37%
MDBH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.7M
Liabilities
$3.2M
Debt to equity
0.05
MDBH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MDBH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$360.4k
Investing
-$23.3k
Financing
$0.0
MDBH vs Capital Market Stocks
Mdb Capital Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.